BR112023019349A2 - Método para produzir uma composição oralmente administrável, forma de dosagem unitária, composição de vacina, usos, kit e produto alimentício ou composição alimentícia - Google Patents

Método para produzir uma composição oralmente administrável, forma de dosagem unitária, composição de vacina, usos, kit e produto alimentício ou composição alimentícia

Info

Publication number
BR112023019349A2
BR112023019349A2 BR112023019349A BR112023019349A BR112023019349A2 BR 112023019349 A2 BR112023019349 A2 BR 112023019349A2 BR 112023019349 A BR112023019349 A BR 112023019349A BR 112023019349 A BR112023019349 A BR 112023019349A BR 112023019349 A2 BR112023019349 A2 BR 112023019349A2
Authority
BR
Brazil
Prior art keywords
asfv
composition
asf
pigs
vaccine
Prior art date
Application number
BR112023019349A
Other languages
English (en)
Inventor
Huu Nguyen Huan
Original Assignee
Igy Immune Tech And Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igy Immune Tech And Life Sciences Inc filed Critical Igy Immune Tech And Life Sciences Inc
Publication of BR112023019349A2 publication Critical patent/BR112023019349A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A23K10/24—Animal feeding-stuffs from material of animal origin from blood
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation

Abstract

método para produzir uma composição oralmente administrável, forma de dosagem unitária, composição de vacina, usos, kit e produto alimentício ou composição alimentícia. a presente invenção refere-se a um método para isolar e preparar vírus vivos da peste suína africana (asf) e uma vacina contra a asf composta por partículas virais da asf, componentes virais da asf e/ou fatores proteicos imunossupressores. a vacina contra a asf pode ser usada para imunizar porcos e javalis ou pode ser usada para imunizar outras espécies além de porcos ou javalis, tais como aves, bovinos, caprinos, coelhos, burros ou cavalos, para gerar imunoglobulinas policlonais com especificidade de amplo espectro pelo asfv. as imunoglobulinas específicas para o asfv podem, então, ser extraídas e purificadas. as imunoglobulinas específicas para o asfv podem fornecer um tratamento agudo de porcos ou javalis infectados pela asf ou tratamento preventivo para porcos ou javalis em risco de asf, por exemplo, que podem ter si-do expostos ao asfv ou indivíduos infectados pelo asfv.
BR112023019349A 2021-03-22 2022-03-22 Método para produzir uma composição oralmente administrável, forma de dosagem unitária, composição de vacina, usos, kit e produto alimentício ou composição alimentícia BR112023019349A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163164309P 2021-03-22 2021-03-22
PCT/IB2022/052621 WO2022201035A1 (en) 2021-03-22 2022-03-22 Vaccines and immunoglobulins targeting african swine fever virus, methods of preparing same, and methods of using same

Publications (1)

Publication Number Publication Date
BR112023019349A2 true BR112023019349A2 (pt) 2024-02-15

Family

ID=83396404

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019349A BR112023019349A2 (pt) 2021-03-22 2022-03-22 Método para produzir uma composição oralmente administrável, forma de dosagem unitária, composição de vacina, usos, kit e produto alimentício ou composição alimentícia

Country Status (6)

Country Link
EP (1) EP4313128A1 (pt)
KR (1) KR20230173115A (pt)
CN (1) CN117529332A (pt)
BR (1) BR112023019349A2 (pt)
CA (1) CA3214456A1 (pt)
WO (1) WO2022201035A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210145221A (ko) * 2019-03-27 2021-12-01 베링거잉겔하임베트메디카게엠베하 아프리카 돼지 열병 바이러스 펩타이드 및 단백질을 포함하는 면역원성 조성물과 백신 및 이들의 용도
US20210252148A1 (en) * 2019-10-31 2021-08-19 Anubis Bio Corporation Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine

Also Published As

Publication number Publication date
CA3214456A1 (en) 2022-09-29
EP4313128A1 (en) 2024-02-07
WO2022201035A1 (en) 2022-09-29
CN117529332A (zh) 2024-02-06
KR20230173115A (ko) 2023-12-26

Similar Documents

Publication Publication Date Title
Fouad et al. Impact of heat stress on meat, egg quality, immunity and fertility in poultry and nutritional factors that overcome these effects: A review
Zur Hausen et al. Dairy cattle serum and milk factors contributing to the risk of colon and breast cancers
Godfroid et al. A “One Health” surveillance and control of brucellosis in developing countries: moving away from improvisation
Obata et al. Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells
Mao et al. Dietary leucine supplementation improves the mucin production in the jejunal mucosa of the weaned pigs challenged by porcine rotavirus
BRPI1014774A2 (pt) preparacao de imunoglobulina enriquecida anti-lps para uso no tratamento e/ou na profilaxia de um disturbio patologico
Van der Klein et al. Genetic relations between natural antibodies binding keyhole limpet hemocyanin and production traits in a purebred layer chicken line
Talukder et al. Trace metal zinc stimulates secretion of antimicrobial peptide LL-37 from Caco-2 cells through ERK and p38 MAP kinase
Polanowski et al. Immunomodulatory activity accompanying chicken egg yolk immunoglobulin Y
Buonsenso et al. Children and COVID‐19: Microbiological and immunological insights
MD3341379T2 (ro) Inhibitori ai EZH2
Liu et al. Protective roles of selenium on nitric oxide and the gene expression of inflammatory cytokines induced by cadmium in chicken splenic lymphocytes
Brun et al. Luminal calcium concentration controls intestinal calcium absorption by modification of intestinal alkaline phosphatase activity
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
Li et al. Infectious bursal disease virus inoculation infection modifies Campylobacter jejuni–host interaction in broilers
BR112022011885A2 (pt) Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia
BR112023019349A2 (pt) Método para produzir uma composição oralmente administrável, forma de dosagem unitária, composição de vacina, usos, kit e produto alimentício ou composição alimentícia
Ferreira et al. Inactivated recombinant Escherichia coli as a candidate vaccine against Clostridium perfringens alpha toxin in sheep
Tsverava et al. Antibody profiling reveals gender differences in response to SARS-COVID-2 infection
Aziz‐Boaron et al. Seroprevalence of bovine ephemeral fever virus in domesticated and wildlife species during epidemic and inter‐epidemic periods (2000–2009) in Israel
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
Khan et al. Immunosuppressant MPA modulates tight junction through epigenetic activation of MLCK/MLC-2 pathway via p38MAPK
BR112022004302A2 (pt) Anticorpos anti-il-27 e usos dos mesmos
EA202190546A1 (ru) Способы лечения инфекций с применением бактерий
JP2008169142A (ja) 食中毒菌に対する抗体の産生方法